Considerations for biomarker-targeted intervention strategies for tuberculosis disease prevention

Tuberculosis

Volumn 109, Issue , 2018, Pages 61-68

  Fiore Gartland, Andrew ^a   Carpp, Lindsay N ^a   Naidoo, Kogieleum ^b   Thompson, Ethan ^c   Zak, Daniel E ^c   Self, Steve ^a   Churchyard, Gavin ^d,e,f   Walzl, Gerhard ^g   Penn Nicholson, Adam ^h   Scriba, Thomas J ^h   Hatherill, Mark ^h  

^a USA   (United States)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

^c SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

^d AURUM INSTITUTE   (South Africa)

^e UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^f SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^g UNIVERSITY OF STELLENBOSCH   (South Africa)

^h UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Biomarker; Correlate of risk; mRNA; Study design; Tuberculosis

Indexed keywords

BIOLOGICAL MARKER; ISONIAZID; RIFAPENTINE; MESSENGER RNA; TRANSCRIPTOME; TUBERCULOSTATIC AGENT;

ANTIBIOTIC PROPHYLAXIS; ARTICLE; DISEASE TRANSMISSION; HIGH RISK POPULATION; HUMAN; INFECTION CONTROL; INFECTION RISK; INTERVENTION STUDY; LOW RISK POPULATION; PERSONALIZED MEDICINE; PRIORITY JOURNAL; RISK ASSESSMENT; SOUTH AFRICA; TRANSCRIPTOMICS; TUBERCULOSIS; BLOOD; CLINICAL DECISION MAKING; DISEASE EXACERBATION; GENE EXPRESSION PROFILING; GENETIC MARKER; GENETIC PREDISPOSITION; GENETICS; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MYCOBACTERIUM TUBERCULOSIS; PHENOTYPE; PREDICTIVE VALUE; PROCEDURES; PROOF OF CONCEPT; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRANSMISSION;

ANTITUBERCULAR AGENTS; BACTERIOLOGICAL TECHNIQUES; CLINICAL DECISION-MAKING; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MYCOBACTERIUM TUBERCULOSIS; PHENOTYPE; PRECISION MEDICINE; PREDICTIVE VALUE OF TESTS; PROOF OF CONCEPT STUDY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RNA, MESSENGER; SOUTH AFRICA; TRANSCRIPTOME; TUBERCULOSIS;

EID: 85042030373     PISSN: 14729792     EISSN: 1873281X     Source Type: Journal    
DOI: 10.1016/j.tube.2017.11.009     Document Type: Article

References (38)

1. Houben, R.M., Dodd, P.J., The global burden of latent tuberculosis infection: a Re-estimation using mathematical modelling. PLoS Med, 13(10), 2016, e1002152.
2. Andrews, J.R., Hatherill, M., Mahomed, H., Hanekom, W.A., Campo, M., Hawn, T.R., et al. The dynamics of QuantiFERON-TB gold in-tube conversion and reversion in a cohort of South African adolescents. Am J Respir Crit Care Med 191:5 (2015), 584–591.
3. Akolo, C., Adetifa, I., Shepperd, S., Volmink, J., Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev(1), 2010 CD000171.
4. Smieja, M.J., Marchetti, C.A., Cook, D.J., Smaill, F.M., Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev(2), 2000 CD001363.
5. Dye, C., Glaziou, P., Floyd, K., Raviglione, M., Prospects for tuberculosis elimination. Annu Rev Public Health 34 (2013), 271–286.
6. Petruccioli, E., Scriba, T.J., Petrone, L., Hatherill, M., Cirillo, D.M., Joosten, S.A., et al. Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosis. Eur Respir J 48:6 (2016), 1751–1763.
7. Hanifa, Y., Grant, A.D., Lewis, J., Corbett, E.L., Fielding, K., Churchyard, G., Prevalence of latent tuberculosis infection among gold miners in South Africa. Int J Tuberc Lung Dis 13:1 (2009), 39–46.
8. Churchyard, G.J., Fielding, K.L., Grant, A.D., A trial of mass isoniazid preventive therapy for tuberculosis control. N Engl J Med 370:17 (2014), 1662–1663.
9. Kunnath-Velayudhan, S., Gennaro, M.L., Immunodiagnosis of tuberculosis: a dynamic view of biomarker discovery. Clin Microbiol Rev 24:4 (2011), 792–805.
10. Zak, D.E., Penn-Nicholson, A., Scriba, T.J., Thompson, E., Suliman, S., Amon, L.M., et al. A blood RNA signature for tuberculosis disease risk: a prospective cohort study. Lancet 387:10035 (2016), 2312–2322.
11. Penn-Nicholson, A., Scriba, T.J., Hatherill, M., White, R.G., Sumner, T., A novel blood test for tuberculosis prevention and treatment. S Afr Med J 107:1 (2016), 4–5.
12. Paez, J.G., Janne, P.A., Lee, J.C., Tracy, S., Greulich, H., Gabriel, S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:5676 (2004), 1497–1500.
13. Jackman, D.M., Miller, V.A., Cioffredi, L.A., Yeap, B.Y., Janne, P.A., Riely, G.J., et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res 15:16 (2009), 5267–5273.
14. Kwak, E.L., Bang, Y.J., Camidge, D.R., Shaw, A.T., Solomon, B., Maki, R.G., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:18 (2010), 1693–1703.
15. Sacher, A.G., Gandhi, L., Biomarkers for the clinical use of PD-1/PD-L1 inhibitors in non-small-cell lung cancer: a review. JAMA Oncol 2:9 (2016), 1217–1222.
16. Janes, H., Brown, M.D., Pepe, M.S., Designing a study to evaluate the benefit of a biomarker for selecting patient treatment. Stat Med 34:27 (2015), 3503–3515.
17. Janes, H., Pepe, M.S., Bossuyt, P.M., Barlow, W.E., Measuring the performance of markers for guiding treatment decisions. Ann Intern Med 154:4 (2011), 253–259.
18. World Health Organization, Guidelines on the management of latent tuberculosis infection. 2015 Geneva.
19. Sterling, T.R., Villarino, M.E., Borisov, A.S., Shang, N., Gordin, F., Bliven-Sizemore, E., et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 365:23 (2011), 2155–2166.
20. Mandrekar, S.J., Sargent, D.J., Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J Clin Oncol 27:24 (2009), 4027–4034.
21. Mandrekar, S.J., Sargent, D.J., Clinical trial designs for predictive biomarker validation: one size does not fit all. J Biopharm Stat 19:3 (2009), 530–542.
22. Freidlin, B., Korn, E.L., Biomarker enrichment strategies: matching trial design to biomarker credentials. Nat Rev Clin Oncol 11:2 (2014), 81–90.
23. Republic of South Africa Department of Health, South African national tuberculosis management guidelines. 2009.
24. Mahomed, H., Ehrlich, R., Hawkridge, T., Hatherill, M., Geiter, L., Kafaar, F., et al. TB incidence in an adolescent cohort in South Africa. PLoS One, 8(3), 2013, e59652.
25. Cliff, J.M., Kaufmann, S.H.E., McShane, H., van Helden, P., O'Garra, A., The human immune response to tuberculosis and its treatment: a view from the blood. Immunol Rev 264:1 (2015), 88–102.
26. Cox, D.R., Regression models and life-tables. J R Stat Soc B, 34(2), 1972 187-+.
27. Kik, S.V., Denkinger, C.M., Casenghi, M., Vadnais, C., Pai, M., Tuberculosis diagnostics: which target product profiles should be prioritised?. Eur Respir J 44:2 (2014), 537–540.
28. Heagerty, P.J., Lumley, T., Pepe, M.S., Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 56:2 (2000), 337–344.
29. Preis, S.R., Spiegelman, D., Zhao, B.B., Moshfegh, A., Baer, D.J., Willett, W.C., Application of a repeat-measure biomarker measurement error model to 2 validation studies: examination of the effect of within-person variation in biomarker measurements. Am J Epidemiol 173:6 (2011), 683–694.
30. Marx, F.M., Dunbar, R., Enarson, D.A., Williams, B.G., Warren, R.M., van der Spuy, G.D., et al. The temporal dynamics of relapse and reinfection tuberculosis after successful treatment: a retrospective cohort study. Clin Infect Dis 58:12 (2014), 1676–1683.
31. Witney, A.A., Bateson, A.L., Jindani, A., Phillips, P.P., Coleman, D., Stoker, N.G., et al. Use of whole-genome sequencing to distinguish relapse from reinfection in a completed tuberculosis clinical trial. BMC Med, 15(1), 2017, 71.
32. McIvor, A., Koornhof, H., Kana, B.D., Relapse, re-infection and mixed infections in tuberculosis disease. Pathog Dis, 75(3), 2017.
33. Jindani, A., Harrison, T.S., Nunn, A.J., Phillips, P.P., Churchyard, G.J., Charalambous, S., et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med 371:17 (2014), 1599–1608.
34. Bloom, C.I., Graham, C.M., Berry, M.P., Wilkinson, K.A., Oni, T., Rozakeas, F., et al. Detectable changes in the blood transcriptome are present after two weeks of antituberculosis therapy. PLoS One, 7(10), 2012, e46191.
35. Malherbe, S.T., Shenai, S., Ronacher, K., Loxton, A.G., Dolganov, G., Kriel, M., et al. Persisting positron emission tomography lesion activity and Mycobacterium tuberculosis mRNA after tuberculosis cure. Nat Med 22:10 (2016), 1094–1100.
36. Stylianou, E., Aukrust, P., Bendtzen, K., Muller, F., Froland, S.S., Interferons and interferon (IFN)-inducible protein 10 during highly active anti-retroviral therapy (HAART)-possible immunosuppressive role of IFN-alpha in HIV infection. Clin Exp Immunol 119:3 (2000), 479–485.
37. Sedaghat, A.R., German, J., Teslovich, T.M., Cofrancesco, J. Jr., Jie, C.C., Talbot, C.C. Jr., et al. Chronic CD4+ T-cell activation and depletion in human immunodeficiency virus type 1 infection: type I interferon-mediated disruption of T-cell dynamics. J Virol 82:4 (2008), 1870–1883.
38. Bern, C., Chagas' disease. N Engl J Med, 373(19), 2015, 1882.